Headline: Adaptive Biotechnologies (ADPT) Prices Upsized $300M Convertible Notes Offering

Adaptive Biotechnologies (ADPT) priced an upsized private offering of $300 million aggregate principal amount of 2.00% Convertible Senior Notes due 2029 on June 17, 2026. The offering, increased from a previously announced $250 million, is expected to close on June 20, 2026. The notes are convertible into ADPT common stock at a rate of 196.4891 shares per $1,000 principal amount, equivalent to approximately $5.09 per share. This represents a 30.8% premium over the stock's closing price of $3.89 per share on June 17, 2026. Initial purchasers hold an option to acquire an additional $45 million in notes. Proceeds from the unsecured, senior obligations are earmarked for general corporate purposes, including working capital, capital expenditures, and potential strategic acquisitions.